239 related articles for article (PubMed ID: 21285988)
1. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.
Wang Y; Wang XY; Subjeck JR; Shrikant PA; Kim HL
Br J Cancer; 2011 Feb; 104(4):643-52. PubMed ID: 21285988
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.
Kim HL; Sun X; Subjeck JR; Wang XY
Cancer Immunol Immunother; 2007 Jul; 56(7):1097-105. PubMed ID: 17146628
[TBL] [Abstract][Full Text] [Related]
3. Temsirolimus for advanced renal cell carcinoma.
Bergmann L; Maute L; Guschmann M
Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
[TBL] [Abstract][Full Text] [Related]
4. Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-Acinetobacter baumannii outer membrane protein A fusion proteins against renal cell carcinoma.
Kim BR; Yang EK; Kim DY; Kim SH; Moon DC; Lee JH; Kim HJ; Lee JC
Clin Exp Immunol; 2012 Jan; 167(1):73-83. PubMed ID: 22132887
[TBL] [Abstract][Full Text] [Related]
5. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
[TBL] [Abstract][Full Text] [Related]
6. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
[TBL] [Abstract][Full Text] [Related]
7. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
8. Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.
Juengel E; Makarević J; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Neoplasia; 2014 Apr; 16(4):291-300. PubMed ID: 24862756
[TBL] [Abstract][Full Text] [Related]
9. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
[TBL] [Abstract][Full Text] [Related]
10. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA
Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
[TBL] [Abstract][Full Text] [Related]
12. Nontuberculous mycobacterial infection after therapy with temsirolimus for metastatic renal cell carcinoma.
Buchler T; Homolka J; Fencl P; Rosova B; Hytych V; Abrahamova J
Tumori; 2013; 99(4):e159-63. PubMed ID: 24326853
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.
Chen S; Cui L; Hu Q; Shen Y; Jiang Y; Zhao J
Biochem Biophys Res Commun; 2020 Sep; 530(1):142-148. PubMed ID: 32828276
[TBL] [Abstract][Full Text] [Related]
14. Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.
Sakamoto H; Yamasaki T; Sumiyoshi T; Takeda M; Shibasaki N; Utsunomiya N; Arakaki R; Akamatsu S; Kobayashi T; Inoue T; Kamba T; Nakamura E; Ogawa O
Cancer Med; 2021 Jan; 10(1):119-134. PubMed ID: 33107222
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
16. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
Wang X; Zhan Y; Zhao L; Alvarez J; Chaudhary I; Zhou BB; Abraham RT; Feuerstein GZ
J Pharmacol Exp Ther; 2011 Nov; 339(2):421-9. PubMed ID: 21835932
[TBL] [Abstract][Full Text] [Related]
17. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100.
Wang XY; Chen X; Manjili MH; Repasky E; Henderson R; Subjeck JR
Cancer Res; 2003 May; 63(10):2553-60. PubMed ID: 12750279
[TBL] [Abstract][Full Text] [Related]
18. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes.
Aalamian M; Fuchs E; Gupta R; Levey DL
Urol Oncol; 2006; 24(5):425-33. PubMed ID: 16962495
[TBL] [Abstract][Full Text] [Related]
19. Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma.
Kobayashi Y; Yamada D; Kawai T; Sato Y; Teshima T; Yamada Y; Nakamura M; Suzuki M; Matsumoto A; Nakagawa T; Hosoi A; Nagaoka K; Karasaki T; Matsushita H; Kume H; Kakimi K
Int J Oncol; 2020 Apr; 56(4):999-1013. PubMed ID: 32319571
[TBL] [Abstract][Full Text] [Related]
20. Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growth in vivo.
Vazakidou ME; Magkouta S; Moschos C; Psallidas I; Pappas A; Psarra K; Kalomenidis I
Respirology; 2015 Nov; 20(8):1263-71. PubMed ID: 26245309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
